Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18358787 | 0.86 | AR (0.45) | ARSLC22A12KIF11 | |
| SCHEMBL1996075 | 0.83 | AR (0.73) | AR | |
| SCHEMBL12151755 | 0.83 | AR (0.52) | ARKIF11 | |
| SCHEMBL29546917 | 0.83 | AR (0.52) | ARKIF11 | |
| SCHEMBL7817776 | 0.82 | AR (0.43) | ARCES2KIF11 | |
| SCHEMBL29421468 | 0.79 | AR (0.50) | ARSLC22A12KIF11 | |
| SCHEMBL325632 | 0.79 | AR (0.50) | ARSLC22A12KIF11 | |
| SCHEMBL6387748 | 0.79 | CES2 (0.50) | ARCES2 | |
| SCHEMBL5203682 | 0.79 | KIF11 (0.53) | ARSLC22A12KIF11 | |
| SCHEMBL9996392 | 0.79 | CES2 (0.46) | ARCES2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| WO-2024126619-A1 | ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING A COMPOUND OF FORMULA (I) AND A COMPOUND OF FORMULA (II), AND DISPLAY DEVICE COMPRISING THE ORGANIC ELECTROLUMINESCENT DEVICE | NOVALED GMBH (DE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024046607-A1 | ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING A COMPOUND OF FORMULA (I) AND A COMPOUND OF FORMULA (II), AND DISPLAY DEVICE COMPRISING THE ORGANIC ELECTROLUMINESCENT DEVICE | NOVALED GMBH (DE) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023232967-A1 | ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING A COMPOUND OF FORMULA (I) AND A COMPOUND OF FORMULA (II), AND DISPLAY DEVICE COMPRISING THE ORGANIC ELECTROLUMINESCENT DEVICE | NOVALED GMBH (DE) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023148215-A1 | 3,6-BIS(CYANOMETHYLIDENE)CYCLOHEXA-1,4-DIENE COMPOUNDS AND THEIR USE IN ORGANIC ELECTRONIC DEVICES | NOVALED GMBH (DE) | 2023-08-10 | — | — | WO | disclosed |
| EP-4223739-A1 | 3,6-BIS(CYANOMETHYLIDENE)CYCLOHEXA-1,4-DIENE COMPOUNDS AND THEIR USE IN ORGANIC ELECTRONIC DEVICES | Novaled GmbH (DE) | 2023-08-09 | — | — | EP | disclosed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-2338935-B1 | FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF | ASAHI GLASS CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-20110172336-A1 | FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2338935-A1 | FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-06-29 | — | — | EP | disclosed |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1716116-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050222213-A1 | Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005080340-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-6362372-B2 | HYDROGENATION OF A TRIFLUOROBENZYLNITRILE BY HYDROGEN IN AN ORGANIC SOLVENT IN THE PRESENCE OF AMMONIA AND A CATALYST COMPRISING A PLATINUM GROUP ELEMENT; EXTREMELY HIGH YIELDS | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-03-26 | — | — | US | disclosed |
| US-20020007086-A1 | Process for producing trifluoromethylbenzylamines | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6175041-B1 | HYDROGENATING A TRIFLUOROMETHYLBENZONITRILE WITH HYDROGEN IN AN ORGANIC SOLVENT IN THE PRESENCE OF AMMONIA, USING A RANEY CATALYST | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007086-A1 | Process for producing trifluoromethylbenzylamines | IDH1, INMT, TH | AR 3622/4885CES2 732/4885SLC22A12 2202/4885 |
| US-20050222213-A1 | Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | GPR119, SLC5A1, AADAC | AR 1407/4885CES2 382/4885SLC22A12 554/4885 |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | SLC5A1, GPR119, SLC5A2 | AR 1440/4885CES2 509/4885SLC22A12 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.